Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function

Hematological Oncology
Iris BreitkreutzMarc S Raab

Abstract

Therapeutic options in heavily pretreated relapsed/refractory multiple myeloma patients are often very limited because of impaired bone marrow function. Bendamustine is effective in multiple myeloma and has a favourable toxicity profile. We hypothesized that dose-intensified bendamustine (180 mg/m(2) , day 1 and 2) followed by autologous blood stem cell support (ASCS) would improve bone marrow function with low post-transplant toxicity in patients with severely impaired haematopoiesis. We analyzed 28 consecutive myeloma patients, with a median of three prior lines of therapy (range 2-7), who had relapsed from the last treatment with very limited bone marrow function and were therefore ineligible for conventional chemotherapy, novel agents or trial enrolment. Dose-intensified bendamustine with ASCS improved haematopoiesis as reflected by increased platelet counts (median 40/nl vs 94/nl, p = 0.0004) and white blood cell counts (3.0/nl vs 4.8/nl, p = 0.02) at day +100. The median time until engraftment of platelets (>50/nl) was 11 days (0-24 days) and of white cell counts (>1.0/nl) 0 days (0-24 days). At least, a minimal response was achieved in 36% of patients. The disease stabilization rate was 50% while the median progression-f...Continue Reading

References

Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Jul 27, 2007·Journal of Cancer Research and Clinical Oncology·Leander GaulRalf Schmidmaier
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lorenzo M LeoniChristina C Niemeyer
Feb 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole BlijlevensUNKNOWN European Blood and Marrow Transplantation Mucositis Advisory Group
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Dec 17, 2008·Hematology·Nikhil C Munshi
Mar 4, 2009·Current Problems in Cancer·S Vincent Rajkumar
May 21, 2009·Seminars in Musculoskeletal Radiology·Andrea Baur-Melnyk, Maximilian F Reiser
Jun 23, 2009·Lancet·Marc S RaabKenneth C Anderson
Feb 18, 2010·European Journal of Medical Research·M MichaelRoland Fenk
Sep 29, 2011·British Journal of Haematology·Elisabeth Grey-DaviesFaith E Davies
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Nov 28, 2012·Journal of Cancer Research and Clinical Oncology·Wolfram PönischDietger Niederwieser
Apr 19, 2013·British Journal of Haematology·Alina S GerrieChristine I Chen
Sep 24, 2013·Expert Opinion on Pharmacotherapy·Massimo GentileFortunato Morabito
Nov 19, 2013·Annals of Hematology·Silvia ParkKihyun Kim

❮ Previous
Next ❯

Citations

Jun 19, 2015·European Journal of Haematology·Massimo GentileFortunato Morabito
Aug 8, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Sarita Rani Jaiswal, Suparno Chakrabarti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.